Single-Cell Profiling Explore the Immunologic Mechanisms of Tumor Relapse in Hepatocellular Carcinoma

Author’s Contribution

The author read and approved the final manuscript.

Funding

None.

Conflict of Interest

None declared.

References

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin 2021;71(3):209-249

[2] Cao M, Li H, Sun D, Chen W.Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020;40(05):205-210

[3] Feng RM, Zong YN, Cao SM, Xu RH.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019;39(01):22

[4] Singal AG, Lampertico P, Nahon P.Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72(02): 250-261

[5] Zheng J, Kuk D, Gönen M, et al.Actual 10-year survivors after resection of hepatocellular carcinoma. Ann Surg Oncol 2017;24(05):1358-1366

[6] Rossi JF, Céballos P, Lu ZY.Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond) 2019;39(01):34

[7] Wu T, Wu X, Wang HY, Chen L.Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun (Lond) 2019;39(01):21

[8] Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017;169(07):1342-1356.e16

[9] Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021;184(02):404-421.e16

[10] Ding X, He M, Chan AWH, et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 2019;157(06):1630-1645.e6

[11] Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018;18(11):671-688

[12] Obar JJ, Jellison ER, Sheridan BS, et al.Pathogen-induced inflammatory environment controls effector and memory CD8þ T cell differentiation. J Immunol 2011;187(10):4967-4978

[13] Amsen D, van Gisbergen KPJM, Hombrink P, van Lier RAW. Tissueresident memory T cells at the center of immunity to solid tumors. Nat Immunol 2018;19(06):538-546

[14] Chen L.Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4(05): 336-347

[15] Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27(01):111-122

RIGHTS & PERMISSIONS

Global Medical Genetics